Kim Sung-Mi, Wang YongQiang, Nabavi Noushin, Liu Yi, Correia Maria Almira
a Department of Cellular & Molecular Pharmacology , University of California San Francisco , San Francisco , CA , USA ;
b Department of Pharmaceutical Chemistry , University of California San Francisco , San Francisco , CA , USA ;
Drug Metab Rev. 2016 Aug;48(3):405-33. doi: 10.1080/03602532.2016.1195403. Epub 2016 Jun 20.
The endoplasmic reticulum (ER)-anchored hepatic cytochromes P450 (P450s) are enzymes that metabolize endo- and xenobiotics i.e. drugs, carcinogens, toxins, natural and chemical products. These agents modulate liver P450 content through increased synthesis or reduction via inactivation and/or proteolytic degradation, resulting in clinically significant drug-drug interactions. P450 proteolytic degradation occurs via ER-associated degradation (ERAD) involving either of two distinct routes: Ubiquitin (Ub)-dependent 26S proteasomal degradation (ERAD/UPD) or autophagic lysosomal degradation (ERAD/ALD). CYP3A4, the major human liver/intestinal P450, and the fast-turnover CYP2E1 species are degraded via ERAD/UPD entailing multisite protein phosphorylation and subsequent ubiquitination by gp78 and CHIP E3 Ub-ligases. We are gaining insight into the nature of the structural determinants involved in CYP3A4 and CYP2E1 molecular recognition in ERAD/UPD [i.e. K48-linked polyUb chains and linear and/or "conformational" phosphodegrons consisting either of consecutive sequences on surface loops and/or disordered regions, or structurally-assembled surface clusters of negatively charged acidic (Asp/Glu) and phosphorylated (Ser/Thr) residues, within or vicinal to which, Lys-residues are targeted for ubiquitination]. Structural inspection of select human liver P450s reveals that such linear or conformational phosphodegrons may indeed be a common P450-ERAD/UPD feature. By contrast, although many P450s such as the slow-turnover CYP2E1 species and rat liver CYP2B1 and CYP2C11 are degraded via ERAD/ALD, little is known about the mechanism of their ALD-targeting. On the basis of our current knowledge of ALD-substrate targeting, we propose a tripartite conjunction of K63-linked Ub-chains, P450 structural "LIR" motifs and selective cellular "cargo receptors" as plausible P450-ALD determinants.
内质网(ER)锚定的肝脏细胞色素P450(P450s)是代谢内源性和外源性物质(即药物、致癌物、毒素、天然产物和化学产物)的酶。这些物质通过增加合成或通过失活和/或蛋白水解降解来减少肝脏P450含量,从而导致具有临床意义的药物相互作用。P450蛋白水解降解通过内质网相关降解(ERAD)发生,涉及两种不同途径中的任何一种:泛素(Ub)依赖性26S蛋白酶体降解(ERAD/UPD)或自噬溶酶体降解(ERAD/ALD)。主要的人肝脏/肠道P450 CYP3A4以及快速周转的CYP2E1亚型通过ERAD/UPD降解,这需要多位点蛋白质磷酸化以及随后由gp78和CHIP E3泛素连接酶进行泛素化。我们正在深入了解参与ERAD/UPD中CYP3A4和CYP2E1分子识别的结构决定因素的性质[即K48连接的多聚泛素链以及由表面环和/或无序区域上的连续序列组成的线性和/或“构象”磷酸化降解基序,或由带负电荷的酸性(Asp/Glu)和磷酸化(Ser/Thr)残基组成的结构组装表面簇,在其内部或附近,赖氨酸残基被靶向进行泛素化]。对选定的人肝脏P450进行结构检查发现,这种线性或构象磷酸化降解基序可能确实是P450-ERAD/UPD的共同特征。相比之下,尽管许多P450,如周转缓慢的CYP2E1亚型以及大鼠肝脏CYP2B1和CYP2C11通过ERAD/ALD降解,但对其ALD靶向机制知之甚少。基于我们目前对ALD底物靶向的了解,我们提出K63连接的泛素链、P450结构“LIR”基序和选择性细胞“货物受体”的三方结合作为合理的P450-ALD决定因素。